AbCellera Biologics Inc.
ABCL
$4.39
$0.092.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 303.40% | -16.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 303.40% | -16.14% | |||
| Cost of Revenue | -7.73% | -7.77% | |||
| Gross Profit | 42.16% | 6.74% | |||
| SG&A Expenses | 15.30% | -0.50% | |||
| Depreciation & Amortization | 2.61% | 127.43% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.34% | 46.04% | |||
| Operating Income | 20.87% | -53.75% | |||
| Income Before Tax | 31.41% | -13.14% | |||
| Income Tax Expenses | 78.04% | 41.65% | |||
| Earnings from Continuing Operations | 23.88% | -33.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.88% | -33.36% | |||
| EBIT | 20.87% | -53.75% | |||
| EBITDA | 23.05% | -120.13% | |||
| EPS Basic | 24.09% | -32.30% | |||
| Normalized Basic EPS | 31.56% | -71.60% | |||
| EPS Diluted | 21.67% | -32.30% | |||
| Normalized Diluted EPS | 31.56% | -71.60% | |||
| Average Basic Shares Outstanding | 0.27% | 0.74% | |||
| Average Diluted Shares Outstanding | 0.27% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||